Tuesday, September 26, 2017

Archive for the Category ‘Featured’

Bonds Nears Turning Point As Retail Investors Pile In

Bonds Nears Turning Point As Retail Investors Pile In

Shorting is a game that should be played with caution, however, if done at the right time can pay off handsomely. Generally, this is done when I see something that’s so drastically overvalued that I can’t resist.

Labeling and Script Use May Cause Problems For Optimer’s New Drug

Labeling and Script Use May Cause Problems For Optimer’s New Drug

Optimer Pharmaceuticals is quickly approaching its May 30th PDUFA as as heavy favourite to win a positive vote from the FDA to market its product, yet it seems that many investors are discounting the potential for a surprise negative outcome. The company is trying to obtain approval for its flagship product, fidaxomicin which could make […]

Three Small Cap Biotechs Primed For Corrections Following ASCO

Three Small Cap Biotechs Primed For Corrections Following ASCO

The month of May has thus far been a very profitable one for investors in a number of small cap biotechs leading up to the June 2011 ASCO meeting, particularly ones that haven’t consequently fared too well once their respective binary events had met its endpoints. First up on the list is Oxigene, Inc. (NASDAQ:OXGN), […]

Atmel Looks To Continue Its Path Of Record Growth And Revenues

Atmel Looks To Continue Its Path Of Record Growth And Revenues

To many, Atmel remains an undiscovered secret within the technology sector, yet recent exclusive semiconductor manufacturing deals with the likes of Samsung, LG, Kyocera, Nokia, HTC, Hitachi, and Motorola, have begun to spur interest. This is a company that is well positioned both technically and fundamentally in order to reach new 52 week highs as […]

Oxigene Nears Marketing Approval of First Anaplastic Thyroid Cancer Drug

Oxigene Nears Marketing Approval of First Anaplastic Thyroid Cancer Drug

With just a few weeks left on the calendar before the world’s largest oncology annual meeting, investors are already gearing up their portfolios for equities that could see exponential gains based on their potentially new research abstracts. The American Society of Clinical Oncology (ASCO) will begin on June 3rd and will feature everything from investigational […]

Uncovering The Hidden Opportunity in Medivation’s Alzheimer’s Drug

Uncovering The Hidden Opportunity in Medivation’s Alzheimer’s Drug

Medivation (NADSAQ:MDVN) was once a thriving biotech with some of the most promising treatments for Alzheimer’s, Huntington Disease and Prostate cancer. Reaching an all-time high of $40 per share back in early 2010, the stock had investors on the edge of their seat in anticipation of what could become, but instead fell short as the […]

Medivation: The Most Promising Upcoming Prostate Cancer Treatment

Medivation: The Most Promising Upcoming Prostate Cancer Treatment

Prostate cancer is the most common form of cancer among men, and two new companies in Medivation and Johnson & Johnson are leading the charge with their experimental new treatments. These two will highlight their findings at The American Society of Clinical Oncology (ASCO), a meeting which has quickly become one of the most important […]

Buyour Rumours For $19 A Share Swirling Around Optimer Pharma Ahead of PDUFA

Buyour Rumours For $19 A Share Swirling Around Optimer Pharma Ahead of PDUFA

Popularity in equities has never been higher than in 2011, with most analysts, including Hilary Kramer raving about the S&P 500 (NYSE:SPY) namely due to $2 trillion dollars worth of cash lying around on the balance sheets of companies. This leads to mergers and acquisitions, along with consolidations which run up prices with the US […]

Optimer Nears First Blockbuster Treatment For $7B CDI Market In 25 Years

Optimer Nears First Blockbuster Treatment For $7B CDI Market In 25 Years

San Diego-based Optimer Pharmaceuticals has spent more than $200 million and a dozen years of effort to get to the point where it can ask the FDA to clear its first product for sale on the U.S. market. And that’s the position Optimer finds itself in now. The company has received little praise from the […]

Apricus Bio Seems Next To Follow In The Footsteps Of Threshold Pharma In SPA Approval

Apricus Bio Seems Next To Follow In The Footsteps Of Threshold Pharma In SPA Approval

The following is a comparison of Apricus Bio, whom is awaiting FDA approval for Special Protocol Assessment on ProvOnco (liver cancer) during 1st quarter 2011 and Threshold Pharma, whom received this designation for TH-302 (soft tissue sarcoma) in the pre-market of Wednesday’s trading session. Few and far between from the investment community had been aware […]

Back to Top

Social Media Profiles

ADVERTISEMENT

BUSINESS NETWORKS

The New York Times logo CNN logo ABC logo CNBC logo